ERBB2 and ductal breast carcinoma in situ: The high agreement rate between IHC and CISH results suggests that it is possible to apply TMAs to DCIS research, with the caveat that, for HER2, the CISH results may be more reliable, countering the discrepancy that can be observed in IHC for either technical or biological reasons.